Kazia Therapeutics Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for Cancer Treatment

Reuters

10/08

<a href="https://laohu8.com/S/KZA.AU">Kazia Therapeutics</a> Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

Kazia Therapeutics Limited has announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for the development of a first-in-class PD-L1 protein degrader program. The partnership centers on NDL2, an advanced PD-L1 protein degrader and a novel candidate in the field of cancer immunotherapy. This agreement marks a significant step forward in Kazia Therapeutics' efforts to expand its oncology pipeline and develop innovative cancer treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-233646), on October 07, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573499646"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573499646\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573499646?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 05:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573499646","market":"nz","top_or_hot":-1,"title":"Kazia Therapeutics Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> has announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for the development of a first-in-class PD-L1 protein degrader program. The partnership centers on NDL2, an advanced PD-L1 protein degrader and a novel candidate in the field of cancer immunotherapy. This agreement marks a significant step forward in Kazia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' efforts to expand its oncology pipeline and develop innovative cancer treatments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-233646), on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kazia Therapeutics Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKazia Therapeutics Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for Cancer Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-08 05:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> has announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for the development of a first-in-class PD-L1 protein degrader program. The partnership centers on NDL2, an advanced PD-L1 protein degrader and a novel candidate in the field of cancer immunotherapy. This agreement marks a significant step forward in Kazia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' efforts to expand its oncology pipeline and develop innovative cancer treatments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-233646), on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KZIA","symbol_name":"Kazia Therapeutics Limited","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDLksNrR:1","article_id":"2573499646","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573499646","pubTimestamp":1759871895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kazia Therapeutics Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for Cancer Treatment. Kazia Therapeutics Limited has announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for the development of a first-in-class PD-L1 protein degrader program. The partnership centers on NDL2, an advanced PD-L1 protein degrader and a novel candidate in the field of cancer immunotherapy. This agreement marks a significant step forward in Kazia Therapeutics' efforts to expand its oncology pipeline and develop innovative cancer treatments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brie","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KZIA":"Kazia Therapeutics Limited","BK4139":"生物科技"},"translate_title":"Kazia Therapeutics与QIMR Berghofer达成独家合作，开发用于癌症治疗的一流PD-L1蛋白降解剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZIA":0.9},"content_text":"Kazia Therapeutics Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for Cancer Treatment\n\n\nKazia Therapeutics Limited has announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for the development of a first-in-class PD-L1 protein degrader program. The partnership centers on NDL2, an advanced PD-L1 protein degrader and a novel candidate in the field of cancer immunotherapy. This agreement marks a significant step forward in Kazia Therapeutics' efforts to expand its oncology pipeline and develop innovative cancer treatments.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-233646), on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}